Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Mutation Research|May 5, 2001
Radiation induced apoptosis in ataxia telangiectasia homozygote, heterozygote and normal cellsD G Bebb, P J Warrington, G de Jong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancerJ M Nabholtz, K Gelmon, M Bontenbal, et al.
Oncology (Williston Park, N.Y.)|March 1, 1994
Phase II trial of megestrol in the supportive care of patients receiving dose-intensive chemotherapyD Osoba, N Murray, K Gelmon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 10, 2012
The sequential use of endocrine treatment for advanced breast cancer: where are we?C Barrios, J F Forbes, W Jonat, et al.
Leukemia & Lymphoma|April 28, 2000
Clinical significance of the t(14;18) and BCL2 overexpression in follicular large cell lymphomaD D Weisenburger, R D Gascoyne, P J Bierman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimenV Westeel, N Murray, K Gelmon, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2013
A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancerJ A Davidson, I Cromwell, S L Ellard, et al.
British Journal of Cancer|August 22, 2014
Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapyK S Courneya, D C McKenzie, J R Mackey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 26, 2021
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysisG Curigliano, V Mueller, V Borges, et al.
Investigational New Drugs|February 6, 2020
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignanciesJ Nehra, P A Bradbury, P M Ellis, et al.
Pageof 5